Savara inc. announces fda response from type c meeting on molgradex for apap development program

Savara inc. announced the response from a type c meeting with the u.s. food and drug administration (fda) regarding the molgradex development program for autoimmune pulmonary alveolar proteinosis (apap). molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (gm-csf). in the written response received by savara on october 1, the fda indicated that the data provided in the briefing package do not provide sufficient evidence of efficacy and safety and did not recommend that the company submit a biologics license application (bla). the company is working to determine the next steps for the molgradex development program.
SVRA Ratings Summary
SVRA Quant Ranking